Ultragenyx stock falls as setrusumab study progresses to final analysis

Ultragenyx Pharma (NASDAQ: RARE) shares dropped approximately 27% in after-hours trading after the company announced its Phase 3 Orbit study for setrusumab in osteogenesis imperfecta did not meet the statistical threshold for early success, necessitating continuation to final analysis in late 2025. Despite this interim setback, Ultragenyx management expressed confidence, citing prior strong Phase 2 results, while analysts like Citi and William Blair reiterated positive ratings. This outlook is supported by the company's robust financial performance, including a 29% revenue increase in 2024 and projected 14-20% growth for 2025, alongside other pipeline advancements such as a Breakthrough Therapy Designation for its Angelman syndrome drug.

Analysis

Ultragenyx Pharma (RARE) experienced a significant after-hours stock decline of approximately 27% following the announcement that its Phase 3 Orbit study for setrusumab did not meet the stringent statistical threshold (p<0.005) for an early stop. The trial will now proceed to its final analysis, anticipated by year-end 2025, where it will be assessed against a lower, more conventional statistical bar (p<0.05). Despite the market's negative reaction to the delayed timeline, Ultragenyx management and sell-side analysts remain optimistic. Management cites strong Phase 2 data, which showed a 67% reduction in fracture rates, while Citi reiterated its Buy rating with a $110 price target. This clinical setback is contrasted by a robust fundamental picture, evidenced by a 29% revenue increase to $560 million in 2024, projected growth of 14-20% for 2025, and a strong liquidity position with a current ratio of 2.4. Further pipeline support comes from the FDA granting Breakthrough Therapy Designation for its Angelman syndrome drug, GTX-102, potentially expediting its development.

Key Decisions for Investors

• Investors should recognize the heightened risk and extended timeline for the setrusumab program, as the final data readout is now delayed until late 2025, creating a significant period of uncertainty.
• The substantial ~27% share price drop may present a buying opportunity for long-term investors with a higher risk tolerance, given the company's strong underlying revenue growth, positive analyst outlooks, and management's confidence in the trial's ultimate success.
• It is crucial to monitor developments in the broader pipeline, particularly the Angelman syndrome drug GTX-102, as its progress now serves as a more critical valuation support and de-risking factor for the company.
• Given the binary nature of the final Orbit study outcome, investors should consider position sizing carefully to manage the downside risk of a potential trial failure, despite the bullish commentary from the company and analysts.